Volume 24, No 8, Aug 2014

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 24 Issue 8, August 2014: 899-900

RESEARCH HIGHLIGHTS

BETs abet Tam-R in ER-positive breast cancer

Prasanna G Alluri^1,2, Irfan A Asangani^2,4 and Arul M Chinnaiyan^2,3,4,5,6

¹Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
²Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
³Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
⁴Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
⁵Department of Urology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
⁶Howard Hughes Medical Institute, University of Michigan Medical School, Ann Arbor, MI 48109, USA Correspondence: Arul M Chinnaiyan, Tel: +1-734-615-4062; Fax: +1-734-615-4055(arul@med.umich.edu)

Epigenetic modifications such as histone acetylation play a central role in the transcriptional regulation of many oncogenic drivers. Accumulating evidence suggests that pharmacological modulation of certain key epigenetic reader proteins such as BRD2/3/4 may serve as an attractive strategy for treatment of many cancers, including tamoxifen-resistant breast cancer.

10.1038/cr.2014.90

FULL TEXT | PDF

Browse 2070